Headquartered in Bedford, MA Fiscal year ends December NASDAQ: LNTH lantheus.com
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic agents used in medical imaging and targeted therapies. Its flagship product, PYLARIFY, is a PSMA-targeted PET imaging agent used for prostate cancer detection. DEFINITY is an ultrasound contrast agent used in cardiology for echocardiography. Neuraceq is a PET imaging agent for neurology applications. The company operates a network of PET manufacturing facilities and serves clinicians across oncology, cardiology, and neurology. Lantheus has entered into a definitive merger agreement with Curium, which would combine the two companies into a radiopharmaceutical platform spanning diagnostics and therapeutics with operations in more than 70 countries. The company also has pipeline candidates including PYLARIFY TruVu (approved March 2026), LNTH-2501 (Gallium-68 edotreotide, under FDA review), and PNT2003 (tentatively approved). Updated
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic agents used in medical imaging and targeted therapies. Its flagship product, PYLARIFY, is a PSMA-targeted PET imaging agent used for prostate cancer detection.
24/7 Wall St.'s 12-month price target for LNTH is $137.83, rated Buy. The Wall Street consensus target is $106.99. LNTH price prediction →
